WO2000000490A3 - 5-ht1f agonists - Google Patents

5-ht1f agonists Download PDF

Info

Publication number
WO2000000490A3
WO2000000490A3 PCT/US1999/014502 US9914502W WO0000490A3 WO 2000000490 A3 WO2000000490 A3 WO 2000000490A3 US 9914502 W US9914502 W US 9914502W WO 0000490 A3 WO0000490 A3 WO 0000490A3
Authority
WO
WIPO (PCT)
Prior art keywords
ht1f agonists
ht1f
agonists
mammal
activating
Prior art date
Application number
PCT/US1999/014502
Other languages
French (fr)
Other versions
WO2000000490A2 (en
Inventor
Joseph Herman Krushinski Jr
Vincent Patrick Rocco
John Mehnert Schaus
Original Assignee
Lilly Co Eli
Joseph Herman Krushinski Jr
Vincent Patrick Rocco
John Mehnert Schaus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Joseph Herman Krushinski Jr, Vincent Patrick Rocco, John Mehnert Schaus filed Critical Lilly Co Eli
Priority to AU49614/99A priority Critical patent/AU4961499A/en
Publication of WO2000000490A2 publication Critical patent/WO2000000490A2/en
Publication of WO2000000490A3 publication Critical patent/WO2000000490A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a compound of formula (I); or a pharmaceutical acid addition salt thereof; which are useful for activating 5-HT1F receptors and inhibiting neuronal protein extravasation in a mammal.
PCT/US1999/014502 1998-06-26 1999-06-24 5-ht1f agonists WO2000000490A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU49614/99A AU4961499A (en) 1998-06-26 1999-06-24 5-HT1f agonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9087298P 1998-06-26 1998-06-26
US60/090,872 1998-06-26
US9495798P 1998-07-31 1998-07-31
US60/094,957 1998-07-31

Publications (2)

Publication Number Publication Date
WO2000000490A2 WO2000000490A2 (en) 2000-01-06
WO2000000490A3 true WO2000000490A3 (en) 2003-04-17

Family

ID=26782729

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/014502 WO2000000490A2 (en) 1998-06-26 1999-06-24 5-ht1f agonists

Country Status (2)

Country Link
AU (1) AU4961499A (en)
WO (1) WO2000000490A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
EP1361225B1 (en) 2001-01-22 2007-11-07 Sankyo Company, Limited Compounds substituted with bicyclic amino groups
ME00549B (en) * 2001-01-29 2011-10-10 Serono Lab Use of il-18 inhibitors for the treatment and/or prevention of heart disease
CN1300116C (en) 2001-04-16 2007-02-14 卫材株式会社 Novel 1H-indazole compound
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
CN1777584A (en) 2003-04-18 2006-05-24 伊莱利利公司 (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht 1f agonists
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
JP2007516266A (en) 2003-12-17 2007-06-21 イーライ リリー アンド カンパニー Substituted (4-aminocyclohexen-1-yl) phenyl and (4-aminocyclohexen-1-yl) pyridinyl compounds as 5-HT1F agonists
WO2011123654A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
CN103044316A (en) * 2013-01-23 2013-04-17 石家庄学院 Method for preparing 1,4-dihydropyridine by using imidazole ionic liquid as catalyst
TWI829107B (en) 2019-07-09 2024-01-11 美商美國禮來大藥廠 Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0303506A2 (en) * 1987-08-13 1989-02-15 Glaxo Group Limited Indole derivatives
EP0313397A1 (en) * 1987-10-23 1989-04-26 The Wellcome Foundation Limited Therapeutic heterocyclic compounds
WO1991018897A1 (en) * 1990-06-07 1991-12-12 The Wellcome Foundation Limited Therapeutic heterocyclic compounds
WO1994014770A1 (en) * 1992-12-21 1994-07-07 Smithkline Beecham Plc Tryptamine analogues as 5-ht1-like agonists
WO1994024127A1 (en) * 1993-04-22 1994-10-27 Pfizer Limited Indole derivatives as 5-h1-like agonists for use in migraine
WO1995032196A1 (en) * 1994-05-19 1995-11-30 Merck Sharp & Dohme Limited Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
EP0714894A1 (en) * 1994-12-01 1996-06-05 Eli Lilly And Company 3-(1,2,3,6-tetrahydro-(1-alkylenearyl)-4-pyridinyl)- and 3-(1-alkylenearyl)-4-piperidinyl-1h-indoles: new 5-HT1f agonists
EP0733628A1 (en) * 1995-03-20 1996-09-25 Eli Lilly And Company 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0303506A2 (en) * 1987-08-13 1989-02-15 Glaxo Group Limited Indole derivatives
EP0313397A1 (en) * 1987-10-23 1989-04-26 The Wellcome Foundation Limited Therapeutic heterocyclic compounds
WO1991018897A1 (en) * 1990-06-07 1991-12-12 The Wellcome Foundation Limited Therapeutic heterocyclic compounds
WO1994014770A1 (en) * 1992-12-21 1994-07-07 Smithkline Beecham Plc Tryptamine analogues as 5-ht1-like agonists
WO1994024127A1 (en) * 1993-04-22 1994-10-27 Pfizer Limited Indole derivatives as 5-h1-like agonists for use in migraine
WO1995032196A1 (en) * 1994-05-19 1995-11-30 Merck Sharp & Dohme Limited Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
EP0714894A1 (en) * 1994-12-01 1996-06-05 Eli Lilly And Company 3-(1,2,3,6-tetrahydro-(1-alkylenearyl)-4-pyridinyl)- and 3-(1-alkylenearyl)-4-piperidinyl-1h-indoles: new 5-HT1f agonists
EP0733628A1 (en) * 1995-03-20 1996-09-25 Eli Lilly And Company 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
US5708008A (en) * 1995-03-20 1998-01-13 Eli Lilly And Company 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)-and 3-(piperidin-4-yl)-1H-indoles: new 5-HT1F agonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOHNSON K W ET AL: "INHIBITION OF NEUROGENIC PROTEIN EXTRAVASATION IN THE DURA VIA 5 -HT1F RECEPTOR ACTIVATION-IMPLICATIONS TO MIGRAINE THERAPY", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 22, no. 1/03, 1 November 1996 (1996-11-01), pages 1330, XP002048755, ISSN: 0190-5295 *
PHEBUS L A ET AL: "CHARACTERIZATION OF LY334370, A POTENT AND SELECTIVE 5-HT1F RECEPTOR AGONIST, IN THE NEUROGENIC DURAL INFLAMMATION MODEL OF MIGRAINE PAIN", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 22, no. 1/03, 1 November 1996 (1996-11-01), pages 1331, XP002048756, ISSN: 0190-5295 *

Also Published As

Publication number Publication date
AU4961499A (en) 2000-01-17
WO2000000490A2 (en) 2000-01-06

Similar Documents

Publication Publication Date Title
AU4831899A (en) 5-HT1F agonists
WO2000006173A8 (en) 5-ht1f agonists
WO2000047559A3 (en) 5-ht1f agonists
IL140338A0 (en) Amino acid derivatives which inhibit dipeptidyl peptidase iv and pharmaceutical compositions containing the same
MX9505182A (en) Therapeutical composition for topical application, containing a p substance antagonist.
GB0018828D0 (en) Alkyl Amino Acid Derivatives useful as pharmaceutical agents
WO2000000490A3 (en) 5-ht1f agonists
ZA967379B (en) Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid compounds and derivatives thereof.
HUP0103452A3 (en) Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors and pharmaceutical compositions containing the compounds
GB9907263D0 (en) Amino acid derivatives
BR9714358A (en) Derivatives of n- (aryl / heteroaryl) amino acid, pharmaceutical compositions comprising them, and methods for inhibiting the release of beta-amyloid peptide and / or its synthesis by using such compounds
HUP0101793A3 (en) Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
AU1704201A (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
HUP9903336A3 (en) Substituted sulfonic acid n-[(aminoiminomethyl)phenylalkyl]-azaheterocyclamide compounds and pharmaceutical compositions containing the same
CA2341031A1 (en) Novel salt form of pantoprazole
AU6518998A (en) Morphinane derivatives and medicinal use thereof
AU2251901A (en) Methods and compounds for inhibiting MRP1
TW200420557A (en) Salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and anti-bacterially pharmaceutical composition comprising the same as active ingredient
IL139884A0 (en) N-substituted derivatives of 5-oximinobarbituric acid
WO1996023771A3 (en) Platelet aggregation inhibitors
EP0952159A3 (en) Use of somatostatin derivatives and/or of phenylhydrazone derivatives as antinflammatory or analgetic agents
WO2003020963A3 (en) Proteins in type 2 diabetes
WO2000050426A3 (en) Furo[3, 2-b]pyridines as 5-ht1f agonists
HUP9900344A3 (en) Process for the preparation of an optically active indoline-2-carboxylic acid or derivative thereof
HUP0201549A2 (en) Quinolinecarboxylic acid derivative or salts thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09720627

Country of ref document: US

122 Ep: pct application non-entry in european phase